

	24 No	vemb	ber 2	2020
Equ	iity l	Res	eai	rch
research	n@arms	ecuriti	es.co	m.ng
	4	-234 1	270	1652

Rating	BUY
Price	<del>N</del> 7.9
FVE	<del>N</del> 10.39
52-week range	<del>N</del> 7.7-8.6
Market Cap. ( <del>N</del> 'bn)	263.34
1-month Avg. Vol	42,465,286.78
Curr. PB	0.45x



Itome Edache Itome.edache@arm.com.ng

Olamide Adeboboye Olamide.adeboboye@arm.com.ng

# United Bank for Africa Plc. (UBA.NL)

## Stock Report

### Earnings advance on higher interest income

- UBA released its Q3 2020 results showing growth in PBT and PAT by 36.2% QoQ and 128.2% QoQ respectively. The faster expansion in PAT reflected a lower effective tax over the period (-94.6% QoQ). Precisely, higher interest income (+15.6% QoQ), lower operating expenses (-17.6% QoQ) as well as a decline in loan loss provisioning (-29% QoQ) anchored the improvements in quarterly numbers, outweighing the sharp fall in NIR (-37.8% QoQ). On interest income, the bank recorded a 25% increase in earnings on investment securities as well as higher interest income on loans to customers (+6.1% QoQ). Akin to other banks, the recognition of AMCON levy in H1 2020 in line with the requirements of IFRIC 21 levies, drove operating expenses southward. Meanwhile, the steep fall in NIR reflects a decline in net fee income (-11% QoQ) and a lower trading income (-60% QoQ) a fallout of FX revaluation losses (-102% QoQ) and lower gain on FX derivatives (-82% QoQ).
- Cumulatively, the company reported a decline in PBT and PAT by 8% YoY and 5.5% YoY respectively over 9M 2020. Compared with our estimates, PBT and PAT represented 82% and 92% of our FY 2020 estimates. Precisely, interest expense came in below our estimate (67% of our FY 2020 estimate) while Non-interest revenue was higher than expected (83% of our estimate). The key drivers of the lower bottom line were higher operating expenses and loan loss provisioning. To start with, operating expenses grew by 19.2% YoY reflecting higher AMCON levy (+12% YoY), premises maintenance costs (+20% YoY), contract services (+52% YoY) and personnel cost (+21% YoY). Consequently, cost to income ratio expanded by 482bps YoY to 65.6%. Meanwhile, loan loss provisioning expanded by 72.2% YoY, translating to a higher cost of risk of 0.6% (+18 bps YoY) over 9M 2020.
- Over 9M 2020, net interest margin remained pressured, declining 69bps YoY to 3.8%, owing to a faster decline in asset yield (-193bps YoY) compared to cost of funds (-151bps YoY). Net interest income rose by 17.1% YoY on the back of higher interest income (+6.5% YoY) and lower interest expense (-5.7% YoY). To buttress, expansion in interest income reflects higher interest earnings on loans and advances as the bank grew loans

by 15.6% YTD to  $\aleph$ 2.38 trillion (+23.07% YoY). On the other hand, lower interest expense on deposits from customers (-11.4% YoY) accounted for the decline in interest expense.

- Elsewhere, Non-interest revenue (NIR) rose marginally by 0.6% YoY as declines in net fee income (-11% YoY) muted increases across FX trading (+2% YoY), gains on derivatives (+115% YoY), as well as FX revaluation gains (+1997% YoY).
- As stated earlier, 9M 2020 interest expense is running below our FY 2020 estimate, therefore we have made a downward adjustment to interest expense to №177 billion (previously: №194.6 billion) and a slight increase in non-interest revenue to №131.6 billion (Previously: №130.5 billion). The impact of our adjustment is an increase in PAT by 9% YoY to №96.9 billion over FY 2020 (previously -6% YoY moderation in PAT). We now have a FVE of №10.39/share (previously: №10.0/share) with an upside of 31.6%, which translates to a **BUY** rating on the stock based on current pricing.

N'million	9M 20	9M 19	YoY (pps)	Q3 20	Q2 20	QoQ
Gross Earnings	424,904	404,983	4.92%	141,933	145,337	-2.34%
Net Interest Income	186,022	158,914	17.06%	66,698	53,907	23.73%
Non-Interest Revenue	107,762	107,080	0.64%	30,377	48,858	-37.83%
Operating Expenses	(192,659)	(161, 621)	19.20%	(60,533)	(73, 469)	-17.61%
Impairment	(11,476)	(6,663)	72.23%	(3,669)	(5,165)	-28.96%
РВТ	90,372	98,233	-8.00%	33,243	24,403	36.23%
PAT	77,132	81,628	-5.51%	32,701	14,330	128.20%
EPS	2.26	2.39	-5.51%	0.96	0.42	128.20%
<b>₩'million</b>	9M 20	9M 19	YoY (pps)	Q2 20	QoQ	
Loans	2,382,683	1,936,012	23.07%	2,186,366	8.98%	
Investment Securities	1,987,543	1,396,175	42.36%	1,977,359	0.52%	
Total Assets	7,059,797	4,960,895	42.31%	6,775,365	4.20%	
Deposits	5,202,228	3,372,903	54.24%	4,800,310	8.37%	
Total Liabilities	6,404,470	4,405,367	45.38%	6,140,632	4.30%	
Net Assets	655,327	555,528	17.96%	634,733	3.24%	
BVPS	19.16	16.24	17.96%	18.56	3.24%	
	9M 20	9M 19	change (pps)	Q3 20	Q2 20	change (pps
Assets Yields	6.43%	8.36%	-1.93%	6.79%	6.04%	0.75%
WACF	2.82%	4.33%	-1.51%	2.96%	2.89%	0.07%
Net Interest Margin	3.77%	4.46%	-0.69%	4.06%	3.38%	0.68%
Cost-Income Ratio	65.58%	60.76%	4.82%	62.36%	71.49%	-9.14%
Cost of Risk	0.64%	0.46%	0.18%	0.60%	0.92%	-0.32%
ROE	15.69%	19.59%	-3.90%	20.28%	9.04%	11.24%

#### **Summary of Results**

# ARM | Classification: PUBLIC

Balance Sheet	2019	2020E	2021E	2022E	2023E
Assets					
Inv. Securities	1,673,938	1,925,029	2,021,280	2,122,344	2,228,461
Net loans	2,061,147	2,323,060	2,436,000	2,570,619	2,699,150
Interest-earning assets	5,239,524	5,978,193	6,273,890	6,600,404	6,930,424
Total assets	4,888,684	5,754,733	6,470,449	7,137,478	7,835,019
Liabilities					
Borrowings	788,730	907,040	1,043,095	1,116,112	1,194,240
Deposits	3,832,884	4,420,381	4,914,579	5,406,037	5,902,384
Interest-bearing liabilities	4,888,684	5,754,733	6,470,449	7,137,478	7,835,019
Total liabilities	5,006,074	5,872,123	6,587,839	7,254,868	7,952,409
Shareholders Equity	597,978	668,267	731,941	801,283	801,283
Income Statement	2019	2020E	2021E	2022E	2023E
Gross Earnings	529,248	556,815	599,413	640,455	675,248
Interest Income	404,830	425,191	459,495	492,853	517,496
Interest Expense	(182,955)	(177,016)	(220, 965)	(243, 904)	(267, 419)
Net Interest Income	221,875	248,175	238,530	248,949	250,077
Trading income	37,627	41,390	45,529	50,082	55,090
Net Fee Income	80,004	82,633	86,028	88,657	93,089
Other Income	6,787	7,601	8,362	8,863	9,572
Non-Interest Revenue	124,418	131,624	139,918	147,601	157,751
Staff Costs	(75,099)	(81,993)	(85,306)	(87,882)	(91, 432)
Other Costs	(142,068)	(147, 414)	(152,007)	(156,390)	(160, 901)
Total Costs	(217,167)	(229,407)	(237,313)	(244,272)	(252,333)
Operating Profit	129,126	150,392	141,135	152,279	155,495
Provision Charge	(18,252)	(23, 231)	(19,488)	(17,994)	(18,894)
РВТ	110,874	127,161	121,647	134,284	136,601
Tax	(22,198)	(30,618)	(29,294)	(33, 674)	(32, 883)
Minorities	2,869	2,909	2,783	3,031	3,124
Net Profit	89,089	96,956	92,766	101,023	104,131

#### **ARM ratings and recommendations**

ARM now employs a two-tier rating system which is based on systemic importance of the security under review and the deviation of our target price for the stock from current market price. We characterize systemic importance as a function of a stock's ranking among the group of top 20 stocks by NSE market capitalization over a trailing 6-month period (minimum) to the review date. We adopt a 5-point rating system for this category of stocks and a 3-point rating system for stocks outside this group. The choice of top 20 stocks arises from the consideration that this group of stocks constitutes >75% of overall market capitalization and stocks outside this group are generally less liquid and individually account for <<1% of market capitalization. For stocks in both categories, the basis for rating subject to target price deviation is outlined below:

<b>TOP 20</b>		NON-TOP 20	
Rating	Deviation	Rating	Deviation
STRONG BUY	>20%	BUY	>20%
OVERWEIGHT	10% - 20 %	NEUTRAL	5% - 20 %
NEUTRAL	0% — 10 %	SELL	<5%
UNDERWEIGHT	-5% - 0%		
SELL	<-5%		

RECOMMENDATION KEY			
Rating	Recommendation		
BUY	Accumulate security to a substantial extent constrained only by portfolio diversification considerations		
OVERWEIGHT	Accumulate security to an extent moderated by cognizance of its benchmark weight		
NEUTRAL	Maintain status quo for security with respect to current holding—i.e. keep if already holding and don't buy otherwise—subject to reas portfolio constraints		
UNDERWEIGHT	Minimize exposure to security taking cognizance of its index weighting		
SELL	Sell-off security completely from portfolio		

Copyright © 2020 ARM Securities Limited ("ARMS").

All rights reserved. Unauthorised use, reproduction, distribution, or disclosure of this document is strictly prohibited.

This material has been issued by ARM Securities Limited, a member of the Asset and Resource Management ("ARM") Group, and a Company regulated by the Nigerian Securities & Exchange Commission. The analyst(s) primarily responsible for preparing this research report, in whole or in part, certifies that with respect to each security or issuer covered; all of the views expressed accurately reflect his/her personal views about the subject securities and issuers and no part of his/her compensation was, is, or will be, directly or indirectly, related to the inclusion of specific recommendations or views in the report.

This research report is based on information from sources that ARMS and its analysts believe to be reliable. Neither ARMS nor any of its research analysts, nor any member of the ARM Group, gives any representation or warranty, express or implied, or undertaking of any kind or assumes responsibility or liability of any kind with respect to the accuracy or completeness of the information set out in this report or any third party's use (or the results of such use) of such information. This report is provided solely for informational purposes and is not to be construed as providing advice, recommendations, or endorsements of any kind whatsoever. The investments and strategies discussed here may not be suitable for all investors; counsel of investment advisor should be obtained with regard to such investments and or strategies. This research report is not a replacement for advice from an accountant, lawyer, personal finance advisor or other category of investment advisor. The investments discussed in this report may oscillate in price or value. Opinions and information provided are made as of the date of the report issue and are subject to change without notice. This research report is not intended as an offer or solicitation for the purchase or sale of any financial instrument. Reference herein to any specific security or financial instrument does not necessarily constitute or imply its endorsement or recommendation by ARMS, its directors, officers, employees or designated agents. Members of ARM may act as broker, advisor or lender, or make a market in any investments or issuers referenced in this report. Further information on any of the securities discussed herein may be obtained upon request to ARMS. By accepting this document, you agree to be bound by the foregoing limitations.